Xencor Inc (XNCR): Edgardo Jr Baracchini , Chief Business Officer of Xencor Inc sold 10,000 shares on Sep 28, 2016. The Insider selling transaction was reported by the company on Sep 28, 2016 to the Securities and Exchange Commission. The shares were sold at $25.47 per share for a total value of $253,474.91 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 6, 2016, Edgardo Jr Baracchini (Chief Business Officer) sold 10,000 shares at $21.06 per share price.On Sep 1, 2016, Bassil I Dahiyat (President and CEO) sold 40,000 shares at $21.80 per share price.Also, On Aug 25, 2016, John J Kuch (Vice President, Finance) sold 25,000 shares at $22.04 per share price.On Aug 24, 2016, John R Desjarlais (Sr. V.P., Research & CSO) sold 16,294 shares at $21.73 per share price.
Xencor Inc: On Tuesday, Sep 27, 2016 heightened volatility was witnessed in Xencor Inc which led to swings in the share price. The shares opened for trading at $24.79 and hit $26.24 on the upside , eventually ending the session at $26.19, with a gain of 6.12% or 1.51 points. The heightened volatility saw the trading volume jump to 3,04,045 shares. The 52-week high of the share price is $26.24 and the company has a market cap of $1,072 M . The 52-week low of the share price is at $9.89.
Xencor Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. The Company uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases cancer and other conditions. The Company’s product pipeline includes three lead XmAb-engineered antibodies which include XmAb5871 XmAb7195 and XmAb5574/MOR208. XmAb5871 is indicated for the treatment of moderate-to-severe rheumatoid arthritis. XmAb7195 is the Company’s wholly owned program being developed for the treatment of severe asthma and allergic diseases. XmAb5574/MOR208 is being developed for the treatment of blood-based cancers.